Regulation (EU) 2022/123 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices figure dans le corpus Pharmaceuticals & Life Sciences parce que son titre officiel correspond à medicinal products. Source: EUR-Lex et dossier du Parlement européen; l'applicabilité à une entreprise dépend de ses activités. Methodology

Regulation (EU) 2022/123 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices: ce que cela signifie pour Pharmaceuticals & Life Sciences

Cette page explique en français pourquoi Regulation (EU) 2022/123 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices est lié à Pharmaceuticals & Life Sciences. La correspondance est fondée sur les termes officiels medicinal products; elle n'est pas un avis juridique.

Acte
32022R0123
Type
règlement
Étape
Procedure completed
Date
25 janvier 2022
Procédure
2020/0321(COD)

Ce que fait l'acte

to reinforce the role of the European Medicines Agency (EMA) in crisis preparedness and management for medicinal products and medical devices. PROPOSED ACT: Regulation of the European Parliament and of the Council. ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council. BACKGROUND: the unprecedented experience of the COVID-19 pandemic has demonstrated that the EU’s ability to coordinate work to ensure the availability of medicinal products and medical devices and facilitate their development is currently...

Lire la fiche complète Regulation (EU) 2022/123 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices

Pourquoi cela compte pour Pharmaceuticals & Life Sciences

Pharmaceutical and life-sciences companies face EU rules on medicines authorisation, clinical trials and supply-chain integrity across the single market. These are the EU acts most likely to apply.

Lex publie la connexion source entre le texte officiel et le secteur; l'impact précis dépend de l'entreprise, de ses produits et de ses marchés.

Autres textes dans le corpus Pharmaceuticals & Life Sciences

Sources primaires

Données © Union européenne. Méthodologie.